Sonoma Pharmaceuticals (SNOA) Competitors $2.79 +0.11 (+4.10%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SNOA vs. EDSA, KPRX, TSBX, RDHL, PHXM, VINC, ADXN, BCLI, NKGN, and SNTIShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include Edesa Biotech (EDSA), Kiora Pharmaceuticals (KPRX), Turnstone Biologics (TSBX), RedHill Biopharma (RDHL), PHAXIAM Therapeutics (PHXM), Vincerx Pharma (VINC), Addex Therapeutics (ADXN), Brainstorm Cell Therapeutics (BCLI), NKGen Biotech (NKGN), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Edesa Biotech Kiora Pharmaceuticals Turnstone Biologics RedHill Biopharma PHAXIAM Therapeutics Vincerx Pharma Addex Therapeutics Brainstorm Cell Therapeutics NKGen Biotech Senti Biosciences Edesa Biotech (NASDAQ:EDSA) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, institutional ownership, earnings and analyst recommendations. Do analysts recommend EDSA or SNOA? Edesa Biotech presently has a consensus target price of $21.00, indicating a potential upside of 556.25%. Given Edesa Biotech's higher possible upside, equities analysts plainly believe Edesa Biotech is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Is EDSA or SNOA more profitable? Edesa Biotech has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -35.91%. Sonoma Pharmaceuticals' return on equity of -65.66% beat Edesa Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Edesa BiotechN/A -137.95% -97.48% Sonoma Pharmaceuticals -35.91%-65.66%-27.20% Which has preferable valuation and earnings, EDSA or SNOA? Sonoma Pharmaceuticals has higher revenue and earnings than Edesa Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdesa BiotechN/AN/A-$8.37MN/AN/ASonoma Pharmaceuticals$12.70M0.21-$4.84M-$10.20-0.27 Does the media refer more to EDSA or SNOA? In the previous week, Edesa Biotech had 4 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 4 mentions for Edesa Biotech and 0 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 0.50 beat Edesa Biotech's score of 0.33 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Edesa Biotech Neutral Sonoma Pharmaceuticals Positive Which has more volatility and risk, EDSA or SNOA? Edesa Biotech has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Do institutionals & insiders believe in EDSA or SNOA? 5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 25.0% of Edesa Biotech shares are held by insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer EDSA or SNOA? Sonoma Pharmaceuticals received 189 more outperform votes than Edesa Biotech when rated by MarketBeat users. However, 77.14% of users gave Edesa Biotech an outperform vote while only 67.50% of users gave Sonoma Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEdesa BiotechOutperform Votes2777.14% Underperform Votes822.86% Sonoma PharmaceuticalsOutperform Votes21667.50% Underperform Votes10432.50% SummaryEdesa Biotech and Sonoma Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Ad Porter & CompanyNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.67M$7.02B$5.39B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.279.47113.8115.12Price / Sales0.21381.571,483.2593.03Price / CashN/A47.3339.6434.05Price / Book0.355.324.665.02Net Income-$4.84M$153.56M$119.06M$225.46M7 Day Performance-6.69%0.12%0.79%0.37%1 Month Performance-5.10%15.23%5.65%3.57%1 Year Performance1,526.82%41.16%36.76%29.42% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma Pharmaceuticals0.9731 of 5 stars$2.79+4.1%N/A+1,612.7%$2.57M$12.73M-0.27180News CoverageEDSAEdesa Biotech2.8316 of 5 stars$3.30-2.9%$21.00+536.4%+0.0%$11.04MN/A0.0020News CoverageGap UpKPRXKiora Pharmaceuticals3.9197 of 5 stars$3.60-2.7%$10.00+177.8%-33.9%$10.99MN/A0.0010Short Interest ↓News CoverageGap DownTSBXTurnstone Biologics3.6284 of 5 stars$0.47flat$2.13+348.3%-86.0%$10.98M$19.31M-0.1482Positive NewsRDHLRedHill Biopharma1.0154 of 5 stars$8.24-1.2%N/A-96.9%$10.63M$6.53M0.00210Gap UpPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049VINCVincerx Pharma3.1275 of 5 stars$0.35flat$2.00+473.1%-59.7%$10.39MN/A-0.2660Gap DownADXNAddex Therapeutics1.5096 of 5 stars$9.75-9.0%$30.00+207.7%+62.1%$10.34M$829,941.00-5.9530Gap UpBCLIBrainstorm Cell Therapeutics4.1483 of 5 stars$1.87-3.1%$30.00+1,504.3%-17.3%$10.26MN/A-0.5440Gap DownNKGNNKGen BiotechN/A$0.28-3.5%N/A-90.5%$10.15M$80,000.00-0.05N/AGap DownSNTISenti Biosciences1.8359 of 5 stars$2.17+0.5%N/A-24.6%$9.89M$2.56M-0.174Positive NewsGap Down Related Companies and Tools Related Companies Edesa Biotech Competitors Kiora Pharmaceuticals Competitors Turnstone Biologics Competitors RedHill Biopharma Competitors PHAXIAM Therapeutics Competitors Vincerx Pharma Competitors Addex Therapeutics Competitors Brainstorm Cell Therapeutics Competitors NKGen Biotech Competitors Senti Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNOA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
